Biggest News Aggregation in the World
📰 T Cell News

Page 33 - T Cell News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from T Cell. Real-time updates on events, politics, business and more.

Researchers compare the development and persistence of antibody and T-cell responses elicited by the mRNA BNT162b2 vaccine or SARS-CoV-2 infection

Researchers comparatively assessed the generation of B lymphocyte-mediated antibody responses and T lymphocyte-mediated cellular responses between mRNA BNT162b vaccinees and mild COVID-19 patients.
Vaccine Elicited Higher Antibody T Cell Responses Coronavirus Disease Covid 19 Ars Cov 2 T Cell B Lymphocyte

New combination of drugs effective against T-cell acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL) is the most common cancer affecting children. The T-ALL form of leukemia that emerges from early T lineage cells has a poorer prognosis than B-lineage ALL. The prognosis for relapsed T-ALL is very poor and new therapies are sorely needed.
United States Eteläuomen Läi North Carolina Olli Lohi Saara Laukkanen Alexandra Veloso

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Elevated Th17 cells associated with increased risk of critical COVID

In a recent article published in the European Journal of Internal Medicine, researchers in France indicated that T cell immune reaction correlates possibly with the chance of critical severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among hospitalized patients.
National Early Warning European Journal Internal Medicine Image Credit Coronavirus Disease Covid 19 Covid 19

Where did Omicron's unique spike gene insertion originate?

In a recent study posted to the medRxiv* pre-print server, scientists at nference Labs investigated the origin of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) new variant of concern (VOC) Omicron's unique spike (S) gene insertion ins214EPE.
Naeblys Shutterstock National Center Image Credit Biotechnology Information Normalized Homology Score Coronavirus Disease Covid 19

Trial of peptide-centered SARS-CoV-2 T-cell activator in B-cell deficient individuals

A recent phase 1/2 study under review at the Nature Portfolio journal and posted to the Research Square* preprint server demonstrated that a peptide-centered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell activator, CoVac-1, was efficient in B-cell deficient people.
Kateryna Kon Research Square Nature Portfolio Positivet Cell S Specifict Cell Coronavirus Disease Covid 19

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science